vimarsana.com

Sintetica Chief Executive Officer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sintetica US launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%

/PRNewswire/ Sintetica S.A., an international pharmaceutical company with manufacturing facilities in Switzerland, announces the launch of Lidocaine.

New jerseyUnited statesSwitzerland generalFrank mulleryNicola caronzoloPrnewswire sinteticaBusiness developmentLidocaine hydrochloride injectionLidocaine injectionSintetica chief executive officerFull prescribing informationSintetica sa

Sintetica SA: Sintetica US launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%

Lidocaine hydrochloride is a short-acting amide-type local anesthetic with a rapid onset and short duration of action and contains no preservatives. MENDRISIO, Switzerland and PRINCETON

Switzerland generalNew jerseyUnited statesPrnewswire sinteticaNicola caronzoloDaniele fontanaFrank mulleryBusiness developmentLidocaine hydrochloride injectionLidocaine injectionSintetica chief executive officerFull prescribing information

Sintetica SA: Harrow Announces U S FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly

San diegoUnited statesSwitzerland generalKostenloser wertpapierhandelJamie webbMarkl baumNicola caronzoloDaniele fontanaDeb hollidayExchange commissionAmerican society of cataractOld international pharmaceutical company sinteticaInstitute for safe medication practicesDrug administrationHolliday communications incFirst approved use

Harrow Announces U S FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

/PRNewswire/ Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative.

San diegoUnited statesSwitzerland generalJamie webbMarkl baumNicola caronzoloDaniele fontanaDeb hollidayAmerican society of cataractInstitute for safe medication practicesDrug administrationHolliday communications incApproved useChloroprocaine hydrochlorideFirst branded ocular anesthetic approvedCanadian markets from

Harrow Announces U S FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years

San diegoUnited statesSwitzerland generalKostenloser wertpapierhandelJamie webbMarkl baumNicola caronzoloDaniele fontanaDeb hollidayExchange commissionAmerican society of cataractOld international pharmaceutical company sinteticaInstitute for safe medication practicesDrug administrationHolliday communications incFirst approved use

vimarsana © 2020. All Rights Reserved.